Clinical and prognostic implications of plasma insulin-like growth factor-1 and vascular endothelial growth factor in patients with hepatocellular carcinoma

Journal of Clinical Oncology

Volumn 29, Issue 29, 2011, Pages 3892-3899

  Kaseb, Ahmed O ^a   Morris, Jeffrey S ^a   Hassan, Manal M ^a   Siddiqui, Adnan M ^a   Lin, E ^a   Xiao, Lianchun ^a   Abdalla, Eddie K ^a   Vauthey, Jean Nicolas ^a   Aloia, Thomas A ^a   Krishnan, Sunil ^a   Abbruzzese, James L ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SOMATOMEDIN C; VASCULOTROPIN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER CLASSIFICATION; CANCER PATIENT; CANCER STAGING; CLINICAL ASSESSMENT; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INSULIN BLOOD LEVEL; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; SURVIVAL TIME; TUMOR DIFFERENTIATION;

AGED; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 80053974116     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.36.0636     Document Type: Article

References (36)

1. Mortality database: WHO Statistical Information System. http://www.who.int/whosis
2. El-Serag HB, Mason AC: Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 340:745-750, 1999 (Pubitemid 29114292)
3. El-Serag HB, Lau M, Eschbach K, et al: Epidemiology of hepatocellular carcinoma in Hispanics in the United States. Arch Intern Med 167:1983-1989, 2007
4. Pons F, Varela M, Llovet JM: Staging systems in hepatocellular carcinoma. HPB (Oxford) 7:35-41, 2005 (Pubitemid 40425755)
5. Kudo M, Chung H, Osaki Y: Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). J Gastroenterol 38:207-215, 2003 (Pubitemid 36527122)
6. A new prognostic system for hepatocellular carcinoma: A retrospective study of 435 patients. Hepatology 28:751-755, 1998
7. Llovet JM, Bru C, Bruix J: Prognosis of hepatocellular carcinoma: The BCLC staging classification. Semin Liver Dis 19:329-338, 1999
8. Tateishi R, Yoshida H, Shiina S, et al: Proposal of a new prognostic model for hepatocellular carcinoma: An analysis of 403 patients. Gut 54:419-425, 2005 (Pubitemid 40299102)
9. Okuda K, Ohtsuki T, Obata H, et al: Natural history of hepatocellular carcinoma and prognosis in relation to treatment: Study of 850 patients. Cancer 56:918-928, 1985 (Pubitemid 15228292)
10. Wilson SR, Greig P, Kaseb AO: Pretreatment assessment of hepatocellular cancer: Expert consensus conference. HPB (Oxford) 12:300-301, 2010
11. Collette S, Bonnetain F, Paoletti X, et al: Prognosis of advanced hepatocellular carcinoma: Comparison of three staging systems in two French clinical trials. Ann Oncol 19:1117-1126, 2008 (Pubitemid 351796337)
12. Huitzil-Melendez FD, Capanu M, O'Reilly EM, et al: Advanced hepatocellular carcinoma: Which staging systems best predict prognosis? J Clin Oncol 28:2889-2895, 2010
13. Bruix J, Sherman M: Management of hepatocellular carcinoma. Hepatology 42:1208-1236, 2005 (Pubitemid 43112690)
14. Bruix J, Sherman M, Llovet JM, et al: Clinical management of hepatocellular carcinoma: Conclusions of the Barcelona-2000 EASL conference - European Association for the Study of the Liver. J Hepatol 35:421-430, 2001 (Pubitemid 32844200)
15. Llovet JM, Di Bisceglie AM, Bruix J, et al: Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 100:698-711, 2008
16. Durand F, Valla D: Assessment of the prognosis of cirrhosis: Child-Pugh versus MELD. J Hepatol 42:S100-S107, 2005 (suppl) (Pubitemid 40364609)
17. Buzzelli G, Dattolo P, Pinzani M, et al: Circulating growth hormone and insulin-like growth factor-I in nonalcoholic liver cirrhosis with or without superimposed hepatocarcinoma: Evidence of an altered circadian rhythm. Am J Gastroenterol 88:1744-1748, 1993 (Pubitemid 23298126)
18. Luo SM, Tan WM, Deng WX, et al: Expression of albumin, IGF-1, IGFBP-3 in tumor tissues and adjacent non-tumor tissues of hepatocellular carcinoma patients with cirrhosis. World J Gastroenterol 11:4272-4276, 2005
19. Su TS, Liu WY, Han SH, et al: Transcripts of the insulin-like growth factors I and II in human hepatoma. Cancer Res 49:1773-1777, 1989
20. Stuver SO, Kuper H, Tzonou A, et al: Insulin-like growth factor 1 in hepatocellular carcinoma and metastatic liver cancer in men. Int J Cancer 87:118-121, 2000 (Pubitemid 30368424)
21. Su WW, Lee KT, Yeh YT, et al: Association of circulating insulin-like growth factor 1 with hepatocellular carcinoma: One cross-sectional correlation study. J Clin Lab Anal 24:195-200, 2010
22. Elsammak MY, Amin GM, Khalil GM, et al: Possible contribution of serum activin A and IGF-1 in the development of hepatocellular carcinoma in Egyptian patients suffering from combined hepatitis C virus infection and hepatic schistosomiasis. Clin Biochem 39:623-629, 2006
23. García-Galiano D, Sánchez-Garrido MA, Espejo I, et al: IL-6 and IGF-1 are independent prognostic factors of liver steatosis and non-alcoholic steatohepatitis in morbidly obese patients. Obes Surg 17:493-503, 2007 (Pubitemid 46850189)
24. Mazziotti G, Sorvillo F, Morisco F, et al: Serum insulin-like growth factor I evaluation as a useful tool for predicting the risk of developing hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: A prospective study. Cancer 95:2539-2545, 2002 (Pubitemid 35424040)
25. Yakar S, Liu JL, Stannard B, et al: Normal growth and development in the absence of hepatic insulin-like growth factor I. Proc Natl Acad Sci U S A 96:7324-7329, 1999 (Pubitemid 29299660)
26. Daughaday WH: The possible autocrine/paracrine and endocrine roles of insulin-like growth factors of human tumors. Endocrinology 127:1-4, 1990
27. Yao DF, Wu XH, Zhu Y, et al: Quantitative analysis of vascular endothelial growth factor, microvascular density and their clinicopathologic features in human hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 4:220-226, 2005 (Pubitemid 40790169)
28. Tseng CS, Lo HW, Chen PH, et al: Clinical significance of plasma D-dimer levels and serum VEGF levels in patients with hepatocellular carcinoma. Hepatogastroenterology 51:1454-1458, 2004
29. Poon RT, Ho JW, Tong CS, et al: Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma. Br J Surg 91:1354-1360, 2004 (Pubitemid 39331462)
30. Kamel L, Nessim I, Abd-el-Hady A, et al: Assessment of the clinical significance of serum vascular endothelial growth factor and matrix metalloproteinase-9 in patients with hepatocellular carcinoma. J Egypt Soc Parasitol 35:875-890, 2005
31. Kaseb AO, Hassan MM, Lin E, et al: V-CLIP: Integrating plasma vascular endothelial growth factor into a new scoring system to stratify patients with advanced hepatocellular carcinoma for clinical trials. Cancer 117:2478-2488, 2010
32. Kaseb AO, Abbruzzese JL, Vauthey JN, et al: I-CLIP: Improved stratification of advanced hepatocellular carcinoma patients by integrating plasma IGF-1 into CLIP score. Oncology 80:373-381, 2011
33. Chan JM, Stampfer MJ, Giovannucci E, et al: Plasma insulin-like growth factor-I and prostate cancer risk: A prospective study. Science 279:563-566, 1998 (Pubitemid 28067285)
34. Hankinson SE, Willett WC, Colditz GA, et al: Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 351:1393-1396, 1998 (Pubitemid 28209997)
35. Ma J, Pollak MN, Giovannucci E, et al: Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst 91:620-625, 1999 (Pubitemid 29194048)
36. Yu H, Spitz MR, Mistry J, et al: Plasma levels of insulin-like growth factor-I and lung cancer risk: A case-control analysis. J Natl Cancer Inst 91:151-156, 1999 (Pubitemid 29042692)